Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Argus Health
Queensland Health
Teva
Cerilliant
Citi
Johnson and Johnson
QuintilesIMS
US Department of Justice

Generated: September 20, 2018

DrugPatentWatch Database Preview

Astrazeneca Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for ASTRAZENECA PHARMS, and when can generic versions of ASTRAZENECA PHARMS drugs launch?

ASTRAZENECA PHARMS has twenty-three approved drugs.

There are seventy-five US patents protecting ASTRAZENECA PHARMS drugs.

Summary for Astrazeneca Pharms
US Patents:75
Tradenames:20
Ingredients:17
NDAs:23

Drugs and US Patents for Astrazeneca Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms MOVANTIK naloxegol oxalate TABLET;ORAL 204760-001 Sep 16, 2014 RX Yes No 7,662,365 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms TAGRISSO osimertinib mesylate TABLET;ORAL 208065-002 Nov 13, 2015 RX Yes Yes 9,732,058 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes 7,151,102 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Astrazeneca Pharms LYNPARZA olaparib TABLET;ORAL 208558-002 Aug 17, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms LOKELMA sodium zirconium cyclosilicate FOR SUSPENSION;ORAL 207078-002 May 18, 2018 RX Yes Yes 9,861,658 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms TUDORZA PRESSAIR aclidinium bromide POWDER, METERED;INHALATION 202450-001 Jul 23, 2012 RX Yes Yes 6,681,768 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Astrazeneca Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Pharms PRILOSEC omeprazole CAPSULE, DELAYED REL PELLETS;ORAL 019810-001 Sep 14, 1989 4,636,499*PED ➤ Try a Free Trial
Astrazeneca Pharms PRILOSEC omeprazole CAPSULE, DELAYED REL PELLETS;ORAL 019810-002 Jan 15, 1998 5,093,342*PED ➤ Try a Free Trial
Astrazeneca Pharms PRILOSEC omeprazole CAPSULE, DELAYED REL PELLETS;ORAL 019810-002 Jan 15, 1998 5,629,305*PED ➤ Try a Free Trial
Astrazeneca Pharms SEROQUEL quetiapine fumarate TABLET;ORAL 020639-003 Sep 26, 1997 4,879,288*PED ➤ Try a Free Trial
Astrazeneca Pharms NEXIUM esomeprazole magnesium CAPSULE, DELAYED REL PELLETS;ORAL 021153-001 Feb 20, 2001 5,093,342 ➤ Try a Free Trial
Astrazeneca Pharms IRESSA gefitinib TABLET;ORAL 206995-001 Jul 13, 2015 5,770,599 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ASTRAZENECA PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 25 mg ➤ Subscribe 2005-08-12
➤ Subscribe Tablets 100 mg, 200 mg and 300 mg ➤ Subscribe 2006-02-21
➤ Subscribe For Injection 20 mg/vial and 40 mg/vial ➤ Subscribe 2009-11-23
➤ Subscribe Inhalation Suspension 0.25 mg/2 mL and 0.5 mg/2 mL ➤ Subscribe 2005-09-15
➤ Subscribe Delayed-release Capsules 20 mg ➤ Subscribe 2007-03-19
➤ Subscribe Tablets 90 mg ➤ Subscribe 2015-07-20
➤ Subscribe Tablets 500 mcg ➤ Subscribe 2015-03-02
➤ Subscribe Tablets 50 mg, 150 mg and 400 mg ➤ Subscribe 2007-02-12
➤ Subscribe Delayed-release 20 mg and 40 mg ➤ Subscribe 2005-08-05
➤ Subscribe Nasal Spray 250 mcg ➤ Subscribe 2012-02-13
➤ Subscribe Inhalation Suspension 1 mg/2 mL ➤ Subscribe 2010-05-28
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2012-03-30
➤ Subscribe Tablets 60 mg ➤ Subscribe 2015-09-30

Non-Orange Book US Patents for Astrazeneca Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,109,210 Quinuclidine derivatives and medicinal compositions containing the same ➤ Try a Free Trial
8,513,279 Quinuclidine derivatives and medicinal compositions containing the same ➤ Try a Free Trial
7,196,098 Quinuclidine derivatives and medicinal compositions containing the same ➤ Try a Free Trial
9,566,276 Phthalazinone derivatives ➤ Try a Free Trial
7,897,617 Quinuclidine derivatives and medicinal compositions containing the same ➤ Try a Free Trial
9,662,352 Microporous zirconium silicate for the treatment of hyperkalemia ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Astrazeneca Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB11/013 United Kingdom ➤ Try a Free Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
15/024 Ireland ➤ Try a Free Trial PRODUCT NAME: NALOXEGOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE OXALATE SALT OF THE ALPHA-EPIMER OF NALOXEGOL; REGISTRATION NO/DATE: EU/1/14/962 20141208
2012000051 Germany ➤ Try a Free Trial PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
3 50005-2015 Slovakia ➤ Try a Free Trial PRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218
C0052 France ➤ Try a Free Trial PRODUCT NAME: SUGAMMADEX SODIUM; REGISTRATION NO/DATE: EU/1/08/466/001-002 20080725
99C0030 Belgium ➤ Try a Free Trial PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Julphar
Covington
Daiichi Sankyo
Harvard Business School
Federal Trade Commission
Moodys
Queensland Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.